Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingxie Fuzheng (QFG) is a traditional Chinese medicine (TCM) formulation investigated for its therapeutic potential in cancer and cancer-associated cachexia. In preclinical models of colon adenocarcinoma-induced cachexia, QFG has been shown to ameliorate muscle wasting and systemic inflammation by modulating the gut microbiota, restoring intestinal barrier integrity, and suppressing the IL-6/NF-κB signaling pathway. Additionally, in hepatocellular carcinoma (HCC) models, QFG exhibits anti-tumor activity by inducing apoptosis through both the death receptor (Fas/FasL) and mitochondrion-dependent (Bax/Bcl-2) pathways, leading to the activation of the caspase cascade (caspase-3, -8, and -9).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingxie fuzheng.